Conotoxin-derived biomimetic coiled cone-shaped peptide as ligand for selective nanodelivery to norepinephrine transporter-expressing neuroblastoma cells

Zivotska, Hana; Mokry, Michal; Rodrigo, Miguel Ángel Merlos; Michalkova, Hana; Kapolkova, Katerina; Šplíchal, Zbyněk; Stokowa-Sołtys, Kamila; Milosavljević, Vedran; Guráň, Roman; Richtera, Lukáš; Haddad, Yazan; Rex, Simona; Heger, Zbyněk

doi:10.1016/j.apmt.2022.101410

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Journal of Nanomedicine 2024:19 3914 homogeneous nanoparticles, ferritins can be simply surface-modified to introduce small molecule/macromolecular targeting ligands to improve the selectivity of nanovehicles targeting diseased tissues. [36][37][38] This strategy could be adopted to promote the targeting of antiviral drugs, thus enhancing therapeutic outcomes. In this regard, we are eager to continue our work.…”

Section: Dovepressmentioning

confidence: 99%

Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant H-ferritin

Vojnikova,

Sukupova,

Stefanik

et al. 2024

IJN

View full text Add to dashboard Cite

Background: As highlighted by recent pandemic outbreaks, antiviral drugs are crucial resources in the global battle against viral diseases. Unfortunately, most antiviral drugs are characterized by a plethora of side effects and low efficiency/poor bioavailability owing to their insolubility. This also applies to the arylnaphthalide lignin family member, diphyllin (Diph). Diph acts as a vacuolar ATPase inhibitor and has been previously identified as a promising candidate with broad-spectrum antiviral activity. However, its physicochemical properties preclude its efficient administration in vivo, complicating preclinical testing. Methods: We produced human recombinant H-ferritin (HsaFtH) and used it as a delivery vehicle for Diph encapsulation through pHmediated reversible reassembly of HsaFtH. Diph nanoformulation was subsequently thoroughly characterized and tested for its nontarget cytotoxicity and antiviral efficiency using a panel of pathogenic viral strain. Results: We revealed that loading into HsaFtH decreased the undesired cytotoxicity of Diph in mammalian host cells. We also confirmed that encapsulated Diph exhibited slightly lower antiviral activity than free Diph, which may be due to the differential uptake mechanism and kinetics of free Diph and Diph@HsaFtH. Furthermore, we confirmed that the antiviral effect was mediated solely by Diph with no contribution from HsaFtH. Conclusion: It was confirmed that HsaFtH is a suitable vehicle that allows easy loading of Diph and production of highly homogeneous nanoparticles dispersion with promising broad-spectrum antiviral activity.

show abstract

Section: Dovepressmentioning

confidence: 99%